SCHEMBL12410705

SCHEMBL12410705

CC(C)c1noc(C(=O)NN)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.46
KDM4E B2RXH2 4/20 0.46
HSD11B1 P28845 1/20 0.34
C3AR1 Q16581 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
ALDH1A1 P00352 5/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MCL1 Q07820 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FABP4 P15090 2/20 0.32
FABP5 Q01469 2/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
P2RX7 Q99572 1/20 0.32
MAPT P10636 1/20 0.32
LMNA P02545 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12410704 0.84 SMPD1 (0.37) GAAKDM4EHSD11B1GPR119SMN1; SMN2
SCHEMBL24408849 0.84 PLK1 (0.35) GAAKDM4EHSD11B1C3AR1GPR119
SCHEMBL27462418 0.79 GPR119 (0.37) KDM4EHSD11B1GPR119ALDH1A1
SCHEMBL1814033 0.77 GPR119 (0.38) HSD11B1GPR119SMN1; SMN2FABP4FABP5
SCHEMBL15932046 0.77 GPR119 (0.38) GAAHSD11B1GPR119ALDH1A1SMN1; SMN2
SCHEMBL23791456 0.76 NPSR1 (0.39) KDM4EHSD11B1GPR119ALDH1A1KMT2A
SCHEMBL8002161 0.76 KDM4E (0.49) GAAKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL12501217 0.73 GAA (0.47) GAAKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL12410860 0.71 GAA (0.56) GAAKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL13195443 0.69 GPR119 (0.35) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD GAA 218/4885KDM4E 3088/4885HSD11B1 3257/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD GAA 218/4885KDM4E 3088/4885HSD11B1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.